华北制药股份有限公司2025年第一次临时股东大会决议公告

Meeting Overview - The first extraordinary general meeting of shareholders was held on December 15, 2025, at the company's conference room in Shijiazhuang [2] - The meeting was conducted with a combination of on-site and online voting, presided over by Mr. Wang Lixin [2][3] Attendance - Out of 9 current directors, 8 attended the meeting, with Mr. Wang Xiujun absent due to work reasons [3] - Out of 5 current supervisors, only 1 attended, with others absent for work reasons [3] - The company secretary and other senior management personnel were present [3] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the supervisory board and amendment of the Articles of Association [4] 2. Revision of the Rules of Procedure for Shareholders' Meetings [4] 3. Revision of the Rules of Procedure for Board Meetings [4] 4. Revision of the Related Party Transaction Management System [4] - All resolutions received more than two-thirds of the valid voting rights [5] Legal Verification - The meeting was witnessed by Beijing DeHeng Law Firm, confirming that the meeting's procedures and resolutions complied with relevant laws and regulations [6] Board Meeting Overview - The 25th meeting of the 11th Board of Directors was held on December 15, 2025, with all 10 directors present [9] - The meeting was convened in accordance with legal and regulatory requirements [9] Board Resolutions - The following resolutions were passed: 1. Election of Mr. Zhang Min as the Vice Chairman of the 11th Board of Directors, effective immediately [10] 2. Adjustment of the members of the Board's Strategy (Investment Decision) and Sustainable Development Committee, with Mr. Zhang Min elected and Mr. Xiao Zhiguang stepping down [12] - All resolutions received unanimous approval [13]